Cassling connects cardiologists with revolutionary AI software

Omaha, Neb. – June 30, 2023 – Cassling has announced a partnership with the goal of benefitting cardiovascular practices throughout the United States.

Cassling will act as a sales agent for EchoSolv™, a revolutionary new cloud-based software from Echo IQ, an AI healthtech company. EchoSolv™, a proprietary artificial intelligence clinical decision support platform, supports cardiology practitioners in diagnosing structural heart disease.

Cassling is uniquely positioned to help healthcare providers understand the outcome-improving implications of this technology. Cassling has extensive expertise in the imaging and cardiovascular markets, and its Growth & Innovation team chose to partner with Echo IQ after listening closely to the needs of customers.

Like Cassling, Echo IQ is committed to creating measurable improvements in patient outcomes and provider experience, unlocking greater efficiencies and lowering costs for healthcare organizations who are asked to do more with less.

"We are excited to partner with Echo IQ and introduce what we believe will be a gamechanger for patients and care teams,” said Elizabeth Grieger, VP of Growth & Innovation at Cassling. “Aortic stenosis is often highly treatable, but accurate disease identification is critical. This innovative technology can be easily integrated into clinical practice and used both as an audit tool and to support real-time diagnosis. We believe our customers will be eager to embrace EchoSolv™ as a means to improve access and outcomes and, ultimately, strengthen community healthcare.”

A recent clinical trial at St Vincent’s Hospital in Sydney, Australia, showed a 72% increase in the detection of severe in-guideline aortic stenosis among patients over cardiologists not using the EchoSolv™ platform. The study was based on 9,189 patients’ echocardiograms and concurred with similar results in previous clinical trials at St Vincent’s Hospital in Melbourne and Beth Israel Deaconess at Harvard Medical School.

“The appointment of Cassling as an agent in the US is highly significant given their impressive reputation in the market,” said Andrew Grover, Executive Chair of Echo IQ. “We are pleased to see our solution sit alongside their stellar offering of complementary products and services.”

Healthcare providers who are interested in learning more about this exciting artificial intelligence software can reach out to Jeff Weinrich, VP of Growth and Innovation Sales at jweinrich@cassling.com.